NUCLEOLIN and neoplasm: One of the most successful tumor-targeted aptamers [40,41], a nucleolin aptamer (AS1411, NucA), is in a phase II trial for the treatment of metastatic renal cell carcinoma and has shown excellent tumor-targeting properties and is non-toxic [42].